Hausen pharmaceutical's first long-acting GLP-1 preparation for the treatment of diabetes in China has been approved for marketing

On May 7, nmpa announced that in the near future, the agency approved the listing of polyethylene glycol loseptide injection (trade name: Flemish) as a class 1 innovative drug for adults to improve blood glucose control in patients with type 2 diabetes through the priority review and approval process Pegylated losenapeptide is a long-acting GLP-1 receptor agonist, which can promote Glucose dependent insulin secretion It can be used to improve blood glucose control in adult type 2 diabetic patients with diet control and exercise, single drug or combined with metformin The launch of pegylated loseptide injection will provide a new treatment for type 2 diabetic patients It is worth mentioning that pegylated losenapeptide is a long-acting GLP-1 receptor agonist independently developed by hausen, and it is also the first long-acting GLP-1 receptor agonist applied for listing in China, which is only injected once a week for the treatment of type 2 diabetes According to the data of pharmaceutical intelligence, this product of hausen Pharmaceutical Co., Ltd was applied for listing in 2017 and was included in the sequence of special review and priority review It lasted for two years and was officially approved for listing on May 7 It is reported that in addition to hausen's long-acting GLP-1 receptor agonist, there are two most popular long-acting GLP-1 preparations in the world, namely, Lilly's dulaglutide and Novo Nordisk's somaluptide injection Lilly's dulaglutide is currently in the clinical review stage, and nole's somaluptide injection has been approved for clinical use on September 26, 2016 Both drugs are imported Drugs Haosen, the local pharmaceutical industry, was approved for the first time, taking the lead in the domestic market of long-acting GLP-1 receptor agonists Statement: This article is to sort out the content, the point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.